- Home
- GOSS vs INBX Comparison
GOSS vs INBX Comparison
Compare GOSS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- INBX
- Stock Information
- Founded
- GOSS 2015
- INBX 2010
- Country
- GOSS United States
- INBX United States
- Employees
- GOSS N/A
- INBX N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- INBX Health Care
- Exchange
- GOSS Nasdaq
- INBX Nasdaq
- Market Cap
- GOSS 586.6M
- INBX 345.8M
- IPO Year
- GOSS 2019
- INBX 2020
- Fundamental
- Price
- GOSS $2.99
- INBX $26.54
- Analyst Decision
- GOSS Strong Buy
- INBX Hold
- Analyst Count
- GOSS 6
- INBX 2
- Target Price
- GOSS $8.60
- INBX N/A
- AVG Volume (30 Days)
- GOSS 4.6M
- INBX 112.9K
- Earning Date
- GOSS 11-06-2025
- INBX 11-13-2025
- Dividend Yield
- GOSS N/A
- INBX N/A
- EPS Growth
- GOSS N/A
- INBX N/A
- EPS
- GOSS N/A
- INBX N/A
- Revenue
- GOSS $40,237,000.00
- INBX $1,400,000.00
- Revenue This Year
- GOSS N/A
- INBX N/A
- Revenue Next Year
- GOSS $30.65
- INBX N/A
- P/E Ratio
- GOSS N/A
- INBX N/A
- Revenue Growth
- GOSS N/A
- INBX N/A
- 52 Week Low
- GOSS $0.66
- INBX $10.81
- 52 Week High
- GOSS $3.60
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- GOSS 59.87
- INBX 52.65
- Support Level
- GOSS $2.61
- INBX $27.51
- Resistance Level
- GOSS $3.60
- INBX $28.86
- Average True Range (ATR)
- GOSS 0.30
- INBX 1.38
- MACD
- GOSS 0.02
- INBX -0.37
- Stochastic Oscillator
- GOSS 50.20
- INBX 8.54
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.